Acticor Biotech News - ALACT

Empower your portfolio: Real-time discussions and actionable trading ideas.

Acticor Biotech annonce les conclusions de l’analyse intermédiaire de futilité dans l’étude GREEN

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 – ALACT– la « Société »), entreprise biopharmaceutique au stade clinique qui développe...

Acticor Biotech: Half-year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative...

Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of June 30, 2024

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug...

Acticor Biotech publishes its 2023 annual results

Annual General Meeting to be held on September 13, 2024, to approve the financial statements for the year ending December 31, 2023 Update on the...

Acticor Biotech: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 mai 2024

Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers Regulatory News: ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT), société...

Acticor Biotech fait le point sur le plan de développement clinique du glenzocimab dans le traitement des urgences cardio-vasculaires

Nouvelles analyses de l’étude de phase 2/3 ACTISAVE démontrant des tendances favorables pour le glenzocimab sur des sous-populations de patients...

Acticor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergencies

Acticor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergencies New analyses of ACTISAVE...

Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of April 30, 2024

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Acticor Biotech (ALACT)

Empower your portfolio: Real-time discussions and actionable trading ideas.

ALACT News

Acticor Biotech annonce les conclusions de l’analyse intermédiaire de futilité dans l’étude GREEN

Acticor Biotech: Half-year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of June 30, 2024

Acticor Biotech publishes its 2023 annual results

Acticor Biotech: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 mai 2024

Acticor Biotech fait le point sur le plan de développement clinique du glenzocimab dans le traitement des urgences cardio-vasculaires

Acticor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergencies

Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of April 30, 2024

ALACT Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Acticor Biotech (ALACT) News

Acticor Biotech (ALACT)

Empower your portfolio: Real-time discussions and actionable trading ideas.

ALACT News

Acticor Biotech annonce les conclusions de l’analyse intermédiaire de futilité dans l’étude GREEN

Acticor Biotech: Half-year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of June 30, 2024

Acticor Biotech publishes its 2023 annual results

Acticor Biotech: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 mai 2024

Acticor Biotech fait le point sur le plan de développement clinique du glenzocimab dans le traitement des urgences cardio-vasculaires

Acticor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergencies

Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of April 30, 2024

ALACT Discussion

Your Recent History